2 days Ago By Defense World Staff
Commonwealth Equity Services LLC bought a new position in shares of biote Corp. ( NASDAQ:BTMD – Free Report ) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 11,000 shares of the company’s stock, valued at approximately $68,000.
Other hedge funds have also modified their holdings of the company. State Street Corp grew its stake in biote by 13.7% in the third quarter.
State Street Corp now owns 475,491 shares of the company’s stock valued at $2,653,000 after purchasing an additional 57,290 shares in the last quarter. Kanen Wealth Management LLC acquired a new stake in biote during the fourth quarter worth $1,791,000. Bank of New York Mellon Corp boosted its holdings in biote by 19.
8% during the fourth quarter. Bank of New York Mellon Corp now owns 105,886 shares of the company’s stock valued at $654,000 after purchasing an additional 17,521 shares in the last quarter. Barclays PLC increased its position in shares of biote by 52.
3% during the 3rd quarter. Barclays PLC now owns 77,196 shares of the company’s stock worth $432,000 after purchasing an additional 26,510 shares in the last quarter. Finally, Charles Schwab Investment Management Inc.
raised its position in biote by 7.4% in the 4th quarter. Charles Schwab Investment Management Inc.
now owns 75,738 shares of the company’s stock valued at $468,000 after purchasing an additional 5,215 shares during the last quarter. 21.68% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In Separately, Craig Hallum reduced their target price on biote from $12.00 to $8.00 and set a “buy” rating on the stock in a report on Thursday, March 13th.
Insider Buying and Selling In other biote news, major shareholder Guines Llc acquired 13,532 shares of the business’s stock in a transaction on Wednesday, April 9th. The stock was purchased at an average price of $3.21 per share, with a total value of $43,437.
72. Following the acquisition, the insider now directly owns 4,156,426 shares of the company’s stock, valued at approximately $13,342,127.46.
This trade represents a 0.33 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink .
Also, Director Stephen Mark Cone bought 38,104 shares of the business’s stock in a transaction dated Monday, March 17th. The shares were bought at an average price of $3.88 per share, with a total value of $147,843.
52. Following the completion of the transaction, the director now owns 160,829 shares in the company, valued at approximately $624,016.52.
This trade represents a 31.05 % increase in their position. The disclosure for this purchase can be found here .
Over the last 90 days, insiders acquired 958,435 shares of company stock worth $3,118,936. Company insiders own 13.90% of the company’s stock.
biote Stock Performance BTMD opened at $3.65 on Friday. The business’s 50-day simple moving average is $4.
06 and its 200 day simple moving average is $5.19. The firm has a market capitalization of $199.
69 million, a PE ratio of 14.04 and a beta of 1.17.
biote Corp. has a 52-week low of $3.04 and a 52-week high of $8.
44. About biote ( Free Report ) biote Corp. operates in practice-building business within the hormone optimization space.
It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. Featured Articles Five stocks we like better than biote 3 Warren Buffett Stocks to Buy Now JPMorgan is a Buy, if You Can Handle The Volatility What is an Earnings Surprise? United States Steel’s Crash: An Unmissable Buying Opportunity 3 Tickers Leading a Meme Stock Revival Rocket Lab Stock: Weathering the Storm, Time for a Comeback? Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.
com's FREE daily email newsletter ..
